Clinical Trial Goal
To find out:
- The highest dose of venetoclax that's safe to give in combination with other standard treatments
- If the combination of venetoclax and other standard treatments is safe and works well to treat multiple myeloma
You may be able to join this trial if you:
- Are 18 years old or older
- Have multiple myeloma
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
Daratumumab is a monoclonal antibody that targets CD38 on certain cells.
Dexamethasone is a drug that reduces inflammation.
Lenalidomide is a drug that blocks growth of cancer cells.
Venetoclax is a small molecule inhibitor that blocks BCL2 in certain cells.
In this trial, you’ll be placed in 1 of 3 groups:
Dexamethasone is a drug that reduces inflammation.
Lenalidomide is a drug that blocks growth of cancer cells.
Venetoclax is a small molecule inhibitor that blocks BCL2 in certain cells.
In this trial, you’ll be placed in 1 of 3 groups:
- Group 1 – Venetoclax plus daratumumab and dexamethasone
- Group 2 – Venetoclax plus dexamethasone and lenalidomide
- Group 3 - Venetoclax plus daratumumab, dexamethasone and lenalidomide
You’ll get treatment in cycles that last 1 month. In each cycle, you'll get:
- Daratumumab - Groups 1 and 3 only – Given as a shot under your skin up to 4 times
- Dexamethasone - A pill that you take by mouth 1 time each week
- Lenalidomide - Groups 2 and 3 only - A pill that you take by mouth 1 time each day for 3 weeks
- Venetoclax - A pill that you take by mouth 1 time each day. The dose you'll get depends on when you start the trial and how safe it has been
You may continue treatment for up to 3 years. You'll have biopsies to see how well the treatment is working. The clinical trial doctors will check your health for up to 3 years.
The Food and Drug Administration (FDA) has approved all of the drugs used in this trial for the treatment of multiple myeloma.
Locations
Mayo Clinic in RochesterRECRUITING
Rochester, Minnesota
Clinical Trials Referral Office, 855-776-0015, mayocliniccancerstudies@mayo.edu
Sponsors
lead: Mayo Clinic
